组蛋白去乙酰化酶2在帕金森病中的作用及机制研究
CSTR:
作者:
作者单位:

1.贵州中医药大学, 贵州 贵阳 550001;2.清镇市第一人民医院 重症医学科, 贵州 贵阳 551400;3.遵义医科大学, 贵州 遵义 563000;4.贵州省人民医院 全科医学科, 贵州 贵阳 550002

作者简介:

通讯作者:

田锦勇,E-mail:tjy8877@163.com;Tel:13809418877

中图分类号:

R741

基金项目:

贵州省中医药管理局中医药、民族医药科学技术研究课题(No:QZYY-2021-011);贵州省科技厅2020年基础研究重大项目(No:黔科合基础〔2020〕1Z059)


Study on the role and mechanism of histone deacetylase 2 in Parkinson's disease
Author:
Affiliation:

1.Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou550001, China;2.Department of Medicine, The First People's Hospital of Qingzhen City, Guiyang, Guizhou551400, China;3.Zunyi Medical University, Zunyi, Guizhou563000, China;4.Department of General Medicine, Guizhou Provincial People's Hospital, Guiyang, Guizhou550002, China

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 旨在探究组蛋白去乙酰化酶2(HDAC2)通过类甲基化转移酶3(METTL3)/细胞因子信号抑制因子3(SOCS3)轴调控帕金森病(PD)中神经元死亡的作用机制。方法 SH-SY5Y细胞分组:Control组、MPP+组、MPP++HDAC2抑制剂组、MPP++HDAC2抑制剂+sh-NC组、MPP++HDAC2抑制剂+sh-METTL3组。观察各组细胞在细胞死亡、细胞活性、HDAC2、METTL3、SOCS3、组蛋白H3赖氨酸18乳酸化(H3K18la)方面的差异。比较oe-NC组及oe-METTL两组SOCS3的m6A修饰水平、METTL3在SOCS3上的富集程度、METTL3表达、SOCS3表达、SOCS3 mRNA稳定性。结果 MPP+ 组与Control组相比,HDAC2基因和蛋白相对表达量升高(P <0.05),细胞死亡率升高(P <0.05),细胞活性及H3K18la在METTL3上的富集程度降低(P <0.05),METTL3、H3K18la、SOCS3均下调(P <0.05)。MPP++HDAC2抑制剂组与MPP+组相比,细胞死亡率降低(P <0.05),细胞活性及H3K18la在METTL3上的富集程度升高(P <0.05),METTL3、H3K18la、SOCS3上调(P <0.05)。MPP++HDAC2抑制剂+sh-NC组与MPP++HDAC2抑制剂组在细胞死亡率、细胞活性、METTL3表达、SOCS3表达上无差异(P >0.05)。MPP++HDAC2抑制剂+sh-METTL3组与MPP++HDAC2抑制剂+sh-NC组相比,细胞死亡率升高(P <0.05),细胞活性降低(P <0.05),METTL3及SOCS3表达下调(P <0.05)。Oe-METTL3与oe-NC组比较,SOCS3的m6A修饰水平及METTL3在SOCS3上的富集程度升高(P <0.05),METTL3及SOCS3升高(P <0.05),SOCS3 mRNA稳定性升高(P <0.05)。结论 在PD中HDAC2通过诱导METTL3组蛋白去乳酸化抑制METTL3表达,这一机制引起SOCS3的m6A修饰水平降低,并导致SOCS3表达下调,进而促进PD发病。

    Abstract:

    Objective To explore the role of histone deacetylase 2 (HDAC2) in modulating the neuron death during Parkinson's disease (PD) via methyltransferase-like 3 (METTL3) / suppressor of cytokine signaling 3 (SOCS3) axis.Methods SH-SY5Y cells were divided into: control, MPP+, MPP+ + HDAC2 inhibitor, MPP+ + HDAC2 inhbitor + sh-NC and MPP+ + HDAC2 inhibitor + sh-METTL3 group, and the alterations in cell death, cell vibility, HDAC2, METTL3, SOCS3 and the lacylation of Lsy in histone 3 (H3K18la) were compared; oe-NC and oe-METTL3 group, and the differences in SOCS3, m6A-modified SOCS3, METTL3 and the enrichment of METTL3 in SOCS3 between the two groups were compared.Results Compared to control group, MPP+ group showed the enhancement of cell death and HDAC2, the decline in METTL3, H3K18la, SOCS3, cell viability and enrichment of H3K18la in METTL3 (P < 0.05). Compared to MPP+ group, MPP+ + HDAC2 inhibitor group displayed the decreases of cell death, and the increases of METTL3, H3K18la, SOCS3, cell viability and enrichment of H3K18la in METTL3 (P < 0.05). There were no significant changes in cell death, METTL3, SOCS3 and cell viability between MPP+ + HDAC2 inhibitor and MPP+ + HDAC2 inhbitor + sh-NC group (P > 0.05). Compared to MPP+ + HDAC2 inhbitor + sh-NC group, MPP+ + HDAC2 inhibitor + sh-METTL3 group showed the elevation of cell death, and the reduction of METTL3, SOCS3 and cell viability (P < 0.05). Compared to oe-NC group, oe-METTL3 group developed the rise in METTL3, SOCS3, SOCS3 stability, m6A-modified SOCS3 and enrichment of METTL3 in SOCS3 (P < 0.05).Conclusion In PD, HDAC2 inhibited METTL3 via inducing the de-lactylation of METTL3, which led to the decrease of m6A-modified SOCS3 and SOCS3 expression. Downregulation of SOCS3 contributed to the occurrence of PD.

    参考文献
    相似文献
    引证文献
引用本文

刘韵,冯丹,刘纷纷,左方娅,郭修红,刘钰淇,陈兰兰,王玉洁,田锦勇.组蛋白去乙酰化酶2在帕金森病中的作用及机制研究[J].中国现代医学杂志,2024,34(21):43-51

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2024-05-27
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2025-01-02
  • 出版日期:
文章二维码